On 16 October 2017, orphan designation (EU/3/17/1922) was granted by the European Commission to Gilead Sciences International Ltd, United Kingdom, for entospletinib for the treatment of acute myeloid leukaemia.
The sponsorship was transferred to Rapport Global Strategic Services Ireland Limited, Ireland, in May 2021.
Treatment of acute myeloid leukaemia
|Date of designation||
|Orphan designation status||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.